Emerging evidence indicates that the NRF2 anti-oxidant pathway mediates resistance to therapy in cancer cells [16, 19, 34, 37, 40, 55] and that IL-6 promotes therapy resistance via NRF2 in SCC [29, 34]. This evidence concerns the gene NFE2L2 and cancer.